Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

374
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
374
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

457
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
457
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

917
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
917
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

710
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
710
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

662
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
662
Pneumonia IV: Management01:28

Pneumonia IV: Management

669
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
669

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.

Annales pharmaceutiques francaises·2021
Same author

Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole.

Neuro-Chirurgie·2021
Same author

Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.

Neurochemical research·2017
Same author

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

SpringerPlus·2015
Same author

Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions.

Journal of neuro-oncology·2013
Same author

Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells.

Biochimie·2012

Related Experiment Video

Updated: Dec 24, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.7K

Dapsone as treatment adjunct in ARDS.

R E Kast1

  • 1IIAIGC Study center, Burlington, Vermont, USA.

Experimental Lung Research
|April 15, 2020
PubMed
Summary
This summary is machine-generated.

Dapsone may reduce acute respiratory distress syndrome (ARDS) lung injury by inhibiting neutrophil migration. Cimetidine can mitigate dapsone-induced methemoglobinemia, a potential ARDS complication.

Keywords:
ARDSIL-8chemokinedapsone

More Related Videos

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

201
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.3K

Related Experiment Videos

Last Updated: Dec 24, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.7K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

201
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

4.3K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Immunology

Background:

  • Pharmacological treatments have historically failed to decrease mortality in acute respiratory distress syndrome (ARDS).
  • Neutrophil accumulation in the lungs, driven by Interleukin-8 (IL-8) chemotaxis, significantly contributes to ARDS pathology and hypoxia.
  • Existing research highlights the role of neutrophils and IL-8 in ARDS pathogenesis.

Purpose of the Study:

  • To explore the potential therapeutic role of dapsone in mitigating ARDS-related lung injury.
  • To investigate dapsone's inhibitory effect on neutrophil chemotaxis towards IL-8 in the context of ARDS.
  • To address the risk of methemoglobinemia associated with dapsone and propose a concurrent treatment strategy.

Main Methods:

  • Review of existing data on neutrophil homing mechanisms and IL-8 gradients in ARDS.
  • Examination of previous findings on dapsone's effects on neutrophil chemotaxis in dermatology and glioblastoma research.
  • Consideration of dapsone's known side effect, methemoglobinemia, and potential mitigation strategies.

Main Results:

  • Neutrophils are known to migrate along IL-8 gradients.
  • Dapsone has demonstrated an ability to inhibit neutrophil chemotaxis to IL-8 in other research contexts.
  • Dapsone administration carries a risk of methemoglobinemia, which is particularly concerning in ARDS patients.

Conclusions:

  • Dapsone presents a potential therapeutic avenue for reducing neutrophil-driven lung damage in ARDS.
  • Concomitant administration of cimetidine is recommended to manage the risk of dapsone-induced methemoglobinemia in ARDS patients.
  • Further investigation into dapsone's efficacy and safety in ARDS is warranted.